Bristol Myers Squibb and Johnson & Johnson to discontinue phase 3 Librexia ACS trial of milvexian treat acute coronary syndrome: Princeton, New Jersey Monday, November 17, 2025, 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback